KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Bionano Genomics' Non-Current Debt history spans 3 years, with the latest figure at $14.9 million for Q1 2021.

  • For Q1 2021, Non-Current Debt changed N/A year-over-year to $14.9 million; the TTM value through Mar 2021 reached $14.9 million, changed N/A, while the annual FY2020 figure was $16.3 million, N/A changed from the prior year.
  • Non-Current Debt for Q1 2021 was $14.9 million at Bionano Genomics, down from $16.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $18.8 million in Q3 2019 and bottomed at $1.8 million in Q2 2020.
  • The 3-year median for Non-Current Debt is $16.3 million (2020), against an average of $12.9 million.
  • The largest YoY upside for Non-Current Debt was 90.47% in 2020 against a maximum downside of 90.55% in 2020.
  • A 3-year view of Non-Current Debt shows it stood at $18.8 million in 2019, then dropped by 13.06% to $16.3 million in 2020, then fell by 8.94% to $14.9 million in 2021.
  • Per Business Quant, the three most recent readings for BNGO's Non-Current Debt are $14.9 million (Q1 2021), $16.3 million (Q4 2020), and $1.8 million (Q3 2020).